Prevalence of <i>KRAS</i>, <i>BRAF</i>, and <i>PIK3CA</i> somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia by Palomba, Grazia et al.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with
colorectal carcinoma may vary in the same population: clues from Sardinia



















Submission date 11 May 2012
Acceptance date 23 August 2012
Publication date 29 August 2012
Article URL http://www.translational-medicine.com/content/10/1/178
This peer-reviewed article can be downloaded, printed and distributed freely for any purposes (see
copyright notice below).
Articles in JTM are listed in PubMed and archived at PubMed Central.
For information about publishing your research in JTM or any BioMed Central journal, go to
Journal of Translational
Medicine
© 2012 Palomba et al. ; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://www.translational-medicine.com/authors/instructions/




© 2012 Palomba et al. ; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Prevalence of KRAS, BRAF, and PIK3CA somatic 
mutations in patients with colorectal carcinoma may 































































 Istituto di Chimica Biomolecolare, CNR, Sassari, Italy 
2
 Servizio Oncologia, ASL1, Sassari, Italy 
3
 Oncologia Medica, Università di Cagliari, Cagliari, Italy 
4
 Oncologia, ASL, Nuoro, Italy 
5
 Oncologia, ASL, Alghero, Italy 
6
 Oncologia, ASL, Oristano, Italy 
7
 Oncologia Medica, AOU, Sassari, Italy 
8
 Anatomia Patologica, Università di Sassari, Sassari, Italy 
9
 Servizio Epidemiologia, ASL1, Sassari, Italy 
10
 Anatomia Patologica, AOU, Sassari, Italy 
*
 Corresponding author. Unit of Cancer Genetics, Institute Biomolecular 
Chemistry (ICB), National Research Council (CNR), Traversa La Crucca 3, Loc. 
Baldinca Li Punti, Sassari 07100, Italy 
Abstract 
Background 
Role of KRAS, BRAF and PIK3CA mutations in pathogenesis of colorectal cancer (CRC) has 
been recently investigated worldwide. In this population-based study, we evaluated the 
incidence rates and distribution of such somatic mutations in genetically isolated population 
from Sardinia. 
Methods 
From April 2009 to July 2011, formalin-fixed paraffin-embedded tissues (N = 478) were 
prospectively collected from Sardinian CRC patients at clinics across the entire island. 
Genomic DNA was isolated from tissue sections and screened for mutations in KRAS, BRAF, 
and PIK3CA genes by automated DNA sequencing. 
Results 
Overall, KRAS tumour mutation rate was 30% (145/478 positive cases). Distribution of 
mutation carriers was surprisingly different within the island: 87/204 (43%) in North Sardinia 
vs. 58/274 (21%) in Middle-South Sardinia (p<0.001). Among 384 CRC cases whose DNA 
was available, only one (0.3%) patient carried a mutation in BRAF gene; PIK3CA was found 
mutated in 67 (17%) patients. A significant inverse distribution of PIK3CA mutation rates 
was observed within Sardinian population: 19/183 (10%) cases from northern vs. 48/201 
(24%) cases from central-southern island (p<0.001). This heterogeneity in frequencies of 
KRAS/PIK3CA somatic mutations is consistent with already-reported discrepancies in 
distribution of germline mutations for other malignancies within Sardinian population. 
Preliminary clinical evaluation of 118 KRAS wild-type patients undergoing anti-EGFR-based 
treatment indicated lack of role for PIK3CA in predicting response to therapy. 
Conclusions 
Our findings support the hypothesis that differences in patients’ origins and related genetic 
backgrounds may contribute to even determine the incidence rate of somatic mutations in 
candidate cancer genes. 
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Introduction 
Colorectal carcinoma (CRC) develops through different pathways, all involving changes at 
the chromosomal or gene levels. It is now widely accepted that sporadic colorectal cancers 
frequently arise from preneoplastic lesions through the activation of oncogenes (KRAS and 
BRAF) as well as the inactivation of tumour suppressor genes (APC, p16, p53, and DCC) and 
mismatch repair genes, such as MLH1 and MSH2 and, to a lower extent, PMS2 and hMSH6 
[1]. In addition, activating mutations in BRAF, a member of the RAF gene family, which 
encode kinases that are regulated by members of the RAS protein family (HRAS, KRAS, and 
NRAS) and mediate cellular responses to growth signals, were found to be associated with 
microsatellite instability (MSI) cancers [2,3]. As stated above, KRAS is the member of the 
RAS gene family mostly mutated in CRC; unlike the BRAF mutations, the KRAS mutations 
have been found to be equally distributed in all tumours, regardless of their MSI status [4]. 
These findings acquire an important role from the pathogenetic point of view since the 
mutations that hit these two genes are reciprocally exclusive. On such a basis, the occurrence 
of an activating mutation at either one of the two genes may be linked to different molecular 








Mutation of KRAS is an established predictor of absence of response to epidermal growth 
factor receptor (EGFR)-targeted agents [5]. The utility of KRAS as a prognostic marker 
remains uncertain. A recent meta-analysis reported that KRAS mutation may act as a negative 
prognostic indicator in both a trans-stage and stage-specific setting [6], whereas other studies, 
such as the large PETACC-3 translational trial [7], reported the absence of any prognostic 
value. On this regard, survival from recurrence was markedly worse in BRAF-mutant tumours 
into the PETACC-3 trial and this observation was consistent with the previously reported 
poor prognosis of BRAF mutations in advanced (stage IV) CRCs [8]. Unlike KRAS 
mutations, BRAF mutations might not be predictive of lack of anti-EGFR therapy benefit [3]. 
Among these genes, nearly all mutations affect the kinase domains at codons 12 or 13 of 
KRAS and codon 600 of BRAF [3,9]. 
In addition to the RAS/RAF/MEK pathway, the phosphatidylinositol 3-kinase 
(PI3K)/AKT/mTOR signaling cascade does participate in regulating cell proliferation and 
survival, apoptosis, and migration [10]. Activation of the PI3K/AKT/mTOR pathway is 
frequently mediated by mutations in the p110α subunit of PI3K, PIK3CA, with most 
mutations (>80%) occurring either in exon 9, which codes for the helical domain, or exon 20, 
which codes for the kinase domain [10]. 
In population-based studies, the prevalence of KRAS, BRAF, and PIK3CA mutations ranges 
from 30% to 40% for KRAS mutations, from 5% to 15% for BRAF mutations, and from 10% 
to 15% for PIK3CA mutations [11]. Somatic mutations of PIK3CA may coexist with either 
KRAS or BRAF mutations within the same tumor [12], but KRAS and BRAF mutations appear 
to be mutually exclusive [13]. 
In Sardinia, which has experienced little immigration due to its remote location and whose 
population has inherited many of the same genetic traits, the contribution of somatic 
mutations in these three genes to the CRC pathogenesis has not been estimated yet. 
Colorectal cancer represents the second principal death-causing malignancy in Sardinia, with 
an incidence (standardized rate, 104 per 100.000 inhabitants per year; Sardinian population 
includes about one million and half inhabitants) quite comparable with that observed in 
Western countries [14]. 
As previously demonstrated by our group for other malignancies (mainly, breast cancer and 
malignant melanoma), the geographical distribution of germline sequence variants across the 
island seems to be significantly heterogeneous, suggesting that the genetic background may 
influence the occurrence of cancer gene mutations [15-17]. In this study, we assessed the 
prevalence and distribution of KRAS, BRAF, and PIK3CA mutations at somatic level among 
478 consecutively-collected CRC patients from Sardinian population. 
Materials and methods 
Samples 
Four hundred and seventy-eight patients with histologically-proven diagnosis of colorectal 
carcinoma (CRC) and regularly participating to the follow-up programs at the Institutions 
across Sardinia island were included into the study. To avoid any bias, CRC patients were 
consecutively collected from April 2009 to September 2011; they were included regardless of 
age at diagnosis and disease characteristics. No CRC case from our series was associated 
with clinically relevant colorectal polyposis. Sardinian origin was ascertained in all cases 
through genealogical studies; for all patients, place of birth of their parents and grandparents 
was assessed in order to assign their geographical origin within the island. Clinical and 
pathological features for the assessment of the disease stage at diagnosis as well as of the 
onset age and tumour anatomical location were confirmed by medical records and/or 
pathology reports. Disease stage classification was assigned according to the American Joint 
Committee on Cancer guidelines [18]. 
Formalin-fixed paraffin embedded tissue samples from CRC patients were obtained from the 
archives of the Institutes and Services of Pathology participating to the study. Tissue samples 
were estimated to contain at least 70% neoplastic cells by light microscopy. 
All patients were informed about the aims of this study and, before the tissue sample was 
collected, gave a written informed consent. The study was reviewed and approved by the 
ethical review board of the University of Sassari. 
Mutation analysis 
All tumour tissues were collected and processed at the laboratory of the Institute of 
Biomolecular Chemistry of Sassari; genomic DNA was isolated from tissue sections using a 
standard protocol and DNA quality assessed for each specimen. In particular, paraffin was 
removed from formalin-fixed paraffin-embedded (FFPE) samples by treatment with Bio-
Clear (Bio-optica, Milan, Italy) and DNA was purified using the QIAamp DNA FFPE Tissue 
kit (QIAGEN Inc., Valencia, CA, USA). 
The coding sequence and splice junctions of exons 2 and 3 in KRAS gene (where all 
pathogenetic mutations occur [9]), exon 15 in BRAF gene (nearly all oncogenic mutations 
have been detected at the kinase domain in exon 15 [19,20]), and exons 9 and 20 in PIK3CA 
gene (they represent the mostly mutated domains of this gene [10,21]) were screened for 
mutations by direct automated sequencing. Briefly, polymerase chain reaction (PCR) was 
performed on 25–50 ng of isolated genomic DNA in a 9700 Thermal cycler (Applied 
Biosystems, Foster City, CA, USA); all PCR-amplified products were directly sequenced 
using an automated fluorescence-based cycle sequencer (ABIPRISM 3100, Applied Bio-
systems, Foster City, CA), as previously described by our group [17]. Primer sequences were 
as follow: KRAS exon 2 forward, TGTGTGACATGTTCTAATATAGTCACAT - exon 2 
reverse, GGTCCTGCACCAGTAATATGC - exon 3 forward, GACTGTGTTTCTCCCTTCT 
- exon 3 reverse, TGGCAAATACACAAAGAAAG; PIK3CA exon 9 forward, GGGAAAAA 
TATGACAAAGAAAGC - exon 9 reverse, CTGAGATCAGCCAAATTCAGTT - exon 20 
forward, CTCAATGATGCTTGGCTCTG - exon 20 reverse, TGGAATCCAGAGTGAGC 
TTTC; BRAF exon 15 forward, TCATAATGCTTGCTCTGATAGGA - exon 15 reverse, 
GGCCAAAAATTTAATCAGTGGA. Protocols for PCR-based assays were designed and 
optimized in our laboratory; they will be available upon request.. Screening for BRAF and 
PIK3CA genes was incomplete in a fifth of patients (94/478; 20%) due to the low amount of 
available tumour tissue samples. 
Statistical analysis 
Statistical analysis for the presence of KRAS, BRAF, or PIK3CA mutations versus different 
variables (sex, age at diagnosis, anatomical site of primary CRC, disease stage, geographical 
origin of patients) was performed by Pearson’s Chi-Square test. The odds ratio (OR) and 95% 
confidence interval (CI) values were calculated by logistic regression analysis. The exact 
coefficient for sample proportion analysis was performed to determine all significant 
parameters (below 0.05 level). All analyses were performed using the statistical package 
SPSS/7.5 per Windows. 
Results 
Paraffin-embedded tumour tissues from a total of 478 patients with advanced colorectal 
carcinoma (CRC) originating from different geographical areas within Sardinia island were 
screened for mutations in candidate genes. Considering the primary tumour, left colon was 
the most frequent anatomical location (left colon, 192 [40%]; right-transverse colon, 172 
[36%]; rectum, 114 [24%]) (Table 1). The median age was 64 years (range, 31–87 years), 
with a preponderance of males (291 men; 61%). At the time of diagnosis, minority of patients 
presented with localized disease (AJCC stage II, 173 [36%] versus AJCC advanced stages III 
and IV, 160 [34%] and 145 [30%], respectively) (Table 1). 
Table 1 Distribution of mutations according to the characteristics of CRC patients 
Characteristic No. (N = 478) KRAS mut No. (N = 384) PI3K mut 
Sex 
Male 293 84 (29%) 231 38* (16%) 
Female 185 61 (33%) 153 29 (19%) 
Tumor site 
Right-transverse colon 172 54 (31%) 138 25* (18%) 
Left colon 192 59 (31%) 151 23 (15%) 
Rectum 114 32 (28%) 95 19 (20%) 
Disease stage 
Stage II 173 44 (25%) 143 22 (15%) 
Stage III 160 56 (35%) 128 25 (20%) 
Stage IV 145 45 (31%) 113 20* (18%) 
Tumor grading 
Well differentiated 56 17 (30%) 44 6 (14%) 
Moderately differentiated 383 118 (31%) 309 54 (17%) 
Poorly differentiated 39 10 (26%) 31 7* (23%) 
Age, years 
< 50 50 16 (32%) 45 5 (11%) 
50-59 116 38 (33%) 102 14 (14%) 
60-69 178 56 (31%) 151 30* (20%) 
70+ 134 35 (26%) 86 18 (21%) 
* 1 patient also mutated in BRAF 
The full coding sequences and intron-exon junctions of the KRAS gene were sequenced in the 
entire series of 478 CRC patients; KRAS mutations were detected in 145 (30%) primary 
tumours (one patient had two mutations, G12D and Q61L). In terms of the gene positions of 
the identified KRAS mutations, 73% (N = 106) of them affected codon 12 and 20% (N = 29) 
affected codon 13, whereas the remaining 7% (N = 11) affected other codons (mainly, codon 
61) (Table 2). All KRAS mutations detected in the present study have been previously 
reported in the Human Gene Mutation Database (HGMD) [22] and in the Catalogue Of 
Somatic Mutations In Cancer (COSMIC) [23]. Considering the patients’ origin within the 
Sardinia island, distribution of mutations was significantly heterogeneous: 87/204 (43%) 
mutated cases in North Sardinia versus 58/274 (21%) in Middle-South Sardinia [p<0.001 
(OR, 2.82; 95% CI, 2.75-2.89); p normalized scientific notation = 6.8 x 10-4] (Figure 1). Such 
discrepancies did not result from incorrect standard sequencing as confirmed by an 
independent duplicate analysis. 
Table 2 Somatic mutations in KRAS gene 
Mutation No. % 
Codon 12 
G12A 13 9 
G12C 11 8 
G12D* 41 28 
G12R 4 3 
G12S 5 3 
G12V 32 22 
Total 106 73 
Codon 49 
E49K 1 0.5 
Codon 13 
G13C 4 3 
G13D 23 16 
G13S/V 2 1 
Total 29 20 
Codon 61 
Q61R 2 1 
Q61L* 7 5 
Total 9 6 
Codon 59 
A59E 1 0.5 
Percentages are referred to mutation frequencies among the 145 positive cases 
* 1 patient with two mutations 
Figure 1 Frequencies of KRAS and PIK3CA mutations across Sardinia. The three 
geographical regions within the island are indicated 
Among available DNA samples, 384 primary tumours were also evaluated for occurrence of 
BRAF (in exon 15) and PIK3CA (in exons 9 and 20) mutations. Overall, mutations were 
detected in 1 (0.3%) patient for BRAF gene and 67 (17.4%) cases for PIK3CA gene. 
The single BRAF-mutated patient presented: a) the substitution of valine by a glutamic acid 
at position 600 (V600E), which has been demonstrated to account for majority (about 90%) 
of the BRAF mutations identified [19,20,24]; and b) a concomitant PIK3CA mutation, 
whereas no KRAS mutation coexisted. For PIK3CA mutations, screening revealed the 
occurrence of six mutations (p.E542K, p.E545A, p.E545G, and p.E545K in exon 9; 
p.M1043I and p.H1047R in exon 20), which have been widely reported in mutation databases 
(HGMD and COSMIC; see above) as commonly associated with CRC, with a recognized 
functional role of the corresponding mutated proteins. The variant p.E545A was the mutation 
with the highest frequency in our series (detected in 54/384 [14%] cases) (Table 3). 
Mutations of PIK3CA and KRAS were found to coexist in 15/384 (3.9%) of cases. 
Table 3 Prevalence of somatic mutations in PIK3CA gene 
Exon Mutated cases (%)* Protein DNA 
9 1 (1.5%) E542K c.1624 G > A 
54 (80.6%) E545A c.1634A > C 
4 (6.0%) E545G c.1634A > G 
1 (1.5%) E545K c.1633 G > A 
20 1 (1.5%) M1043I c.3129 G > T 
6 (8.9%) H1047R c.3140A > G 
*percentages are referred to the series of 67 positive cases 
Table 4 summarizes the distribution and relationship of the somatic mutations identified in 
the series of 384 CRC tumours for all three candidate genes. Altogether, a mutation of at least 
one gene was discovered in about half (174/384; 45.3%) of CRC cases; in other words, 
54.7% (N = 210) primary tumours displayed a wild-type genetic status in these three genes 
(Table 4). 
Table 4 Frequencies of somatic mutations in the series of 384 patients screened for all 
three genes, according to the geographical origin 
Patients’ origin KRAS KRAS + PIK3CA BRAF + PIK3CA PIK3CA wild-type 
% % % % % 
North Sardinia (N = 183) 66 8 0 11 98 
36.1 4.4 0 6.0 53.5 
Middle-South Sardinia 
(N = 201) 
41 7 1 40 112 
20.4 3.5 0.5 19.9 55.7 
Total (N = 384) 107 15 1 51 210 
27.8 3.9 0.3 13.3 54.7 
Considering the patients’ origin, PIK3CA mutations were found to be inversely distributed as 
compared to the KRAS mutations: 19 (10%) out of 183 patients from North Sardinia versus 
48 (24%) out of 201 patients from Middle-South Sardinia were found to carry mutations in 
exons 9 and 20 of the PIK3CA gene (Table 4; Figure 1). As for KRAS, such a heterogeneous 
distribution of PIK3CA mutations was found highly significant [p<0.001 (OR, 2.45; 95% CI, 
2.36-2.55); p normalized scientific notation = 5.9 x 10-4]. To avoid any putative artefact, such 
discrepancies were again confirmed in independent duplicate sequencing experiments. As 
shown in Figure 2, majority (63%) of KRAS mutations were found in patients from North 
Sardinia whereas more than two thirds (70%) of PIK3CA mutations were detected in patients 
from Middle-South Sardinia. No difference in distribution of KRAS and PIK3CA mutations 
between rural and urban areas, both globally and within the two (North vs. Middle-South) 
geographical regions was observed. 
Figure 2 Geographical distribution of mutation carriers in the series of 384 patients 
screened for all three genes. (A) Entire island. (B) Northern and (C) Central-Southern 
regions. Prevalence of (D) KRAS- and (E) PIK3CA-mutated patients according to the 
geographical origin 
Both KRAS and PIK3CA mutations were evaluated for association with several pathological 
parameters: sex, age at diagnosis, anatomical location of primary CRC, tumour grading, 
AJCC stage of the disease. In our series, no significant correlation was found between the 
occurrence of KRAS or PIK3CA mutations and all analyzed parameters. However, a non-
significant trend for PIK3CA mutations to be associated with a older age of onset and a 
higher tumour grade was observed (see Table 1). Absence of any association between the 
different variables was also confirmed by a multivariate analysis. 
Finally, we preliminarily evaluated the association between PIK3CA mutations and response 
to the treatment with anti-EGFR monoclonal antibodies in patients with wild-type KRAS. 
Among the 118 KRAS mutation negative patients for whom results were available (105 [89%] 
treated with cetuximab in association with systemic chemotherapy and 13 [11%] with 
panitumumab alone), the objective response rate at first evaluation was 30% (N = 35; no 
complete clinical response was registered) (Table 5). In this subset of patients, a slight but not 
significant difference in rates of partial responses was observed between PIK3CA-mutated 
(7/29; 24%) and PIK3CA-wild-type (28/89; 31%) cases (Table 5). 
Table 5 Clinical response to anti-EGFR therapy in KRAS wild-type patients 
  KRAS wt 
KRAS wt (N = 118) PI3K wt (N = 89) PI3K mut (N = 29) 
PR 35 (30%) 28 (31%) 7 (24%) 
SD 58 (49%) 45 (51%) 13 (45%) 
PD 25 (21%) 16 (18%) 9 (31%) 
PR, partial response; SD, stable disease; PD, progression disease. wt, wild-type 
Discussion 
In this study, we have reported the prevalence of somatic mutations in KRAS, PIK3CA, and 
BRAF genes among patients with advanced colorectal carcinoma from Sardinia, whose 
population shows genetic peculiarity due to geographical isolation and strong genetic drift 
[25]. Prevalence of candidate gene mutations may vary among distinct populations due to 
concurrence of different environmental factors and genetic backgrounds. Furthermore, 
patients’ geographical origin within the same population may also account for different 
mutation rates in pathogenetic cancer genes, as already demonstrated for different types of 
cancer in Sardinian population by our group [15-17]. In summary, we observed a moderate 
rate of KRAS mutations (145/478; 30.3%) or PIK3CA mutations (67/384; 17.4%) and a very 
low rate of BRAF mutations (1/384; 0.3%) in a cohort of primary colorectal carcinomas. 
Prevalence of KRAS mutations in our series is consistent with data from literature, indicating 
that such an alteration can be found in 30-40% of colorectal carcinomas [6]. Controversial 
data have been instead published about the PIK3CA mutation rates, ranging from 7% [26] to 
30% [27] of CRC cases presenting a mutated PIK3CA. In the present study, all detected 
PIK3CA variants have been previously demonstrated to be oncogenic in CRC cellular models 
[28] and commonly associated with colorectal carcinoma (17%; see Table 3); the mutation 
rate was therefore comparable with that described in majority of previous reports. 
The most surprising finding was the nearly lack of BRAF mutations in our series. In recent 
meta-analyses, the BRAF V600E mutation - which represents the most common mutation in 
BRAF gene (more than 90% of cases) - was detected in about 9% of primary colorectal 
carcinomas [29,30]. One could speculate that the very low frequency of BRAF mutation 
detected in our series may be somehow due to patients’ origin or, in other words, to the 
peculiarity of the genetically-isolated Sardinian population. On this regard, it cannot be 
excluded that different pathogenetic mechanisms of transformation could occur in different 
populations. Microsatellite instability (MSI), a recognized marker of a tendency for 
replication errors in human cancers, has been widely indicated as a factor associated with 
higher frequency of mutations in BRAF gene among colorectal carcinomas [29,31,32]. 
Although such an analysis was not conducted in the present study, Sardinian CRC population 
has been previously demonstrated to present an incidence of MSI similar to that observed in 
other CRC populations from Western countries [33,34]. Therefore, this factor could not 
explain the striking discrepancy on the BRAF mutation prevalence in our series. 
Considering the two prevalent alterations, KRAS and PIK3CA mutations were more or less 
equally distributed among the different patients’ subsets, and no statistically significant 
correlation with sex, onset age (though patients with older age at diagnosis and a higher 
tumour grade are more likely to present with a PIK3CA mutation), disease stage, primary 
CRC location, or tumour grading was observed (see Table 1). 
As schematically represented in Figure 2, we made comparisons between prevalence of 
KRAS and PIK3CA mutations within different geographical areas of the island. In a 
population sharing a quite similar lifestyle and diet habit across the island (moreover, 
smokers were homogeneously distributed among patients of different origin - though such an 
information from medical records was available in only about 70% of cases from our series), 
the observation that a higher frequency of KRAS mutations was found in CRC cases from 
North Sardinia (43% vs. 21%) whereas a higher prevalence of PIK3CA mutations was found 
in patients from South Sardinia (24% vs. 10%) strongly suggest that different “genetic 
background” may also induce discrepant penetrance and distribution of somatic mutations in 
candidate cancer genes. As for similar data reported by our group in breast cancer and 
melanoma, the geographical distribution of the genetic variants in the island seems to be 
related to the specific large areas of Sardinia, which reflect its ancient history: the North area, 
delimited by the mountain chain crossing Sardinia and linguistically different from the rest of 
the island; and the Middle-South area, land of the ancient Sardinian population and domain of 
pastoral culture. Nevertheless, our findings clearly indicate that mutation frequency for any 
candidate cancer gene needs to be accurately evaluated in each geographical area within 
every single population. Due to this unexpected heterogeneity in distribution of somatic 
mutations in such few main genes, we already started the collection of tumour DNA samples 
from Sardinian colorectal cancer patients in order to perform a whole-exome sequencing and 
define a more comprehensive pattern of mutations in this population. 
Finally, although performed on a limited number of CRC cases, our preliminary data seemed 
to indicate no correlation between PIK3CA mutations and response to the anti-EGFR 
treatment in patients with wild-type KRAS (objective responses were considered at first 
evaluation only) (see Table 5). A second study focused on evaluating such clinical aspects in 
a larger subset of patients is ongoing. 
KRAS mutations are considered as an early event in the sequential accumulation of molecular 
alterations underlying the progression from colorectal adenoma to malignant carcinoma, 
resulting in an important tumour growth advantage. During the recent past years, a targeted 
therapy with monoclonal antibodies (cetuximab and panitumumab), blocking the EGFR-
driven cell proliferation signals, has been introduced into the therapy of metastatic colorectal 
cancer [35,36]. No significant response to therapy with anti-EGFR antibodies have been 
observed in colorectal cancer patients exhibiting KRAS mutations [37]. Moreover, majority of 
colorectal carcinomas exhibiting wild-type KRAS do not respond to such therapies either 
[36]. These phenomena are expected from the molecular point of view, since EGFR tyrosine 
kinase transmits proliferation signals via RAS-GTPase on the cell membrane inner surface, 
which in turn can bind effector proteins such as RAF or PIK3CA kinases [38]. Therefore, the 
occurrence of functional integrity of the RAS-driven pathways - BRAF-MEK-ERK and 
PIK3CA-AKT - is necessary in order to really interfere with tumour cell growth through 
inhibition of EGFR target. In other words, the assessment of mutational status of BRAF and 
PIK3CA genes into the KRAS wild-type population may indeed improve the selection of 
patients presenting such a functional integrity of the RAS-driven pathways (though we are 
aware that additional alterations in downstream effectors may intervene). In contrast to 
KRAS, the heterogeneity of BRAF and PIK3CA mutations has not been adequately 
investigated in colorectal cancer thus far. 
In the present study, because some somatic mutations (in BRAF and PIK3CA genes or in 
KRAS and PIK3CA genes) occurred concomitantly in a given patient, which is in line with 
literature, a total of about 45% of all patients showed at least one mutation in any of these 
three genes (see Table 4). Therefore, our data suggest that including mutation analyses for 
BRAF and PIK3CA in addition to KRAS into a standard diagnostic setting of colorectal cancer 
would allow the identification of an additional fraction (in our case, about 15%) of patients 
who cannot be considered as “true wild-type” for such main proliferation-controlling genes. 
However, whether or not these additional patients might benefit from EGFR-specific 
antibody therapy has to be verified in prospective clinical studies. 
Conclusions 
Although Sardinian population is considered genetically homogeneous, the results obtained 
in the present study may represent a clear indication that: a) differences into the genetic 
background - related to distinct patients’ origin within the island - may account for different 
mutation rates in candidate cancer genes (in our series, KRAS and PIK3CA), even at somatic 
level; and b) mutation frequency for any candidate cancer gene needs to be accurately 
evaluated in each geographical area. 
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